27 Sep 2022 Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Press Releases
27 Sep 2022 Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke Press Releases PARIS–(
27 Sep 2022 Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD Press Releases BEDFORD…
27 Sep 2022 DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO Press Releases CAMBRIDGE, Mass.–(
27 Sep 2022 Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-2 Press Releases GUANGZHOU, China–(…
27 Sep 2022 Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 Press Releases BOSTON–(
27 Sep 2022 AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors Press Releases CONSHOHOCKEN, Pa.–(
27 Sep 2022 Aktana Welcomes New Medical Affairs Lead from IBM Watson Health (Now Merative) Press Releases SAN FRANCISCO–…
27 Sep 2022 Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer Press Releases MONROE…
26 Sep 2022 Partnering with Patients and Caregivers in Clinical Research Press Releases A version of this article was previously published in the
